로고
About us
Company overview
History
Leadership
Business Strategy
Contact us
Platform Technology
Antibody Discovery
Bispecific Antibody
Platform
Development Capability
Pipeline
Overview
Media Room
Notice
News
Gallery
Careers
Culture
Recruiting Information
언어선택
ENG
KOR
ENG
전체메뉴
About us
Company overview
History
Leadership
Business Strategy
Contact us
Platform Technology
Antibody Discovery
Bispecific Antibody
Platform
Development Capability
Pipeline
Overview
Media Room
Notice
News
Gallery
Careers
Culture
Recruiting Information
News
Innovative Medicines based on
ImmunoModulatory Biologics
Media Room
About us
Platform Technology
Pipeline
Media Room
Careers
News
Notice
News
Gallery
IMB-101, Selection of the top 10 excellent projects for KDDF 2023
Date
2024-02-19 17:55:19
View
551
For more information, please visit :
IMBiologics
News
(full article available in Korean)
Prev
汉腾生物与韩国IMBiologics达成战略合作
Next
Patent registration of ePENDY platform technology in Korea
목록
President(CEO) : Gyongsik Ha
260, Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea